Abstract:Influenza is a highly contagious disease that causes annual epidemics and occasional pandemics. Birds are believed to be the source of newly emerging pandemic strains, including highly pathogenic avian influenza viruses of the subtype H7. The aim of the study: to evaluate the ability of the recombinant human adenovirus, serotype 5, which expresses genes of influenza A highly conserved antigens (ion channel M2 and nucleoprotein NP), to provide protection to laboratory mice against infection with a lethal dose of avian influenza virus, subtype H7. To achieve this goal, it was necessary to adapt influenza A virus, subtype H7 for reproduction in the lungs of mice, to characterise it, and to use it for evaluation of the protective properties of the recombinant adenovirus. Materials and methods: avian influenza virus A/Chicken/NJ/294508-12/2004 (H7N2) was adapted for reproduction in the lungs of mice by repeated passages. The adapted strain was sequenced and assessed using hemagglutination test, EID50 and LD50 for laboratory mice. BALB/c mice were immunised once with Ad5-tet-M2NP adenovirus intranasally, and 21 days after the immunisation they were infected with a lethal dose (5 LD50) of influenza virus A/Chicken/NJ/294508-12/2004 (H7N2) in order to assess the protective properties of the recombinant adenovirus. The level of viral shedding from the lungs of the infected mice was evaluated by titration of the lung homogenates in MDCK cell culture on days 3 and 6 after infection. The level of specific antibodies to H7 avian influenza virus was determined by indirect enzyme immunoassay. Results: the use of Ad5-tet-M2NP adenovirus for immunisation of the mice ensured 100% survival of the animals that had disease symptoms (weight loss) after their infection with the lethal dose (5 LD50) of H7 avian influenza virus. The study demonstrated a high post-vaccination level of humoral immune response to H7 avian influenza virus. The virus titer decreased significantly by day 6 in the lungs of mice that had been immunised with Ad5-tet-M2NP compared to the control group. Conclusion: the Ad5-tetM2NP recombinant adenovirus can be used to create a candidate pandemic influenza vaccine that would protect against avian influenza viruses, subtype H7, in particular.

Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice

Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection

Protective efficacy of a novel recombinant influenza virus carrying partial human metapneumovirus F protein epitopes

Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice

Protection against human metapneumovirus ( hMPV) conveyed by influenza virus vectors carrying multiple epitope antigens of hMPV

A Bivalent Live-Attenuated Vaccine Candidate Elicits Protective Immunity Against Human Adenovirus Types 4 And 7

A chimeric influenza virus vaccine expressing fusion protein epitopes induces protection from human metapneumovirus challenge in mice

An Advax-CpG adjuvanted recombinant H5 hemagglutinin vaccine protects mice against lethal influenza infection

Construction and cellular immune response induction of HA-based alphavirus replicon vaccines against human-avian influenza (H5N1).

The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response

Enhancement of Mouse Immune Response by Recombinant Adenovirus Co-Expressing VP1-2A of Foot-and-mouth Disease Virus and Porcine IFN-α

Intranasal Immunization with a Replication-Deficient Adenoviral Vector Expressing the Fusion Glycoprotein of Respiratory Syncytial Virus Elicits Protective Immunity in BALB/c Mice.

Neutralizing monoclonal antibodies protect against human adenovirus type 55 infection in transgenic mice and tree shrews

Intranasal Vaccination with A Helper-Dependent Adenoviral Vector Enhances Transgene-Specific Immune Responses in Balb/C Mice

Protecting Mice from H7 Avian Influenza Virus by Immunisation with a Recombinant Adenovirus Encoding Influenza A Virus Conserved Antigens

Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease

Construction of Recombinant Influenza Virus Carrying Human Metapneumovirus Epitopes

Both haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge

Intranasal Immunization with a Helper-Dependent Adenoviral Vector Expressing the Codon-Optimized Fusion Glycoprotein of Human Respiratory Syncytial Virus Elicits Protective Immunity in BALB/c Mice

Comparative Immunogenicity of Recombinant Adenovirus-Vectored Vaccines Expressing Different Forms of Hemagglutinin (HA) Proteins from the H5 Serotype of Influenza A Viruses in Mice.

Construction of Replication-defective Recombinant Adenoviruses Expressing Influenza Virus Hemagglutinin and Study on Its Immune Responses